Postmenopausal Osteoporosis
Most providers start osteoporosis therapy without full assessment of secondary causes
NEW ORLEANS —Few providers conduct a complete assessment of secondary causes of osteoporosis before initiating medication, according to findings presented at the AACE annual meeting.
Most providers start osteoporosis therapy without full assessment of secondary causes
NEW ORLEANS —Few providers conduct a complete assessment of secondary causes of osteoporosis before initiating medication, according to findings presented at the AACE annual meeting.
Nutrition, stress reduction can affect women’s health conditions through gut health
Susan Weiner, MS, RDN, CDN, CDCES, FADCES, continues her conversation with Audrey Fleck, MS, RDN, about associations between gut dysbiosis — an unhealthy imbalance of microbes in the gut — and diseases associated with reproductive hormones.
Appendicular lean mass associated with bone mass in postmenopausal women
Among postmenopausal women living in Brazil, lower appendicular lean mass was independently associated with low bone mass, according to findings of a cross-sectional study published in Menopause.
Denosumab biosimilar displays noninferiority in postmenopausal patients with osteoporosis
A denosumab biosimilar candidate demonstrated noninferior efficacy to its reference product, with similar safety profile, in postmenopausal patients with osteoporosis, according to data published in Arthritis Research & Therapy.
Bone mineral benefits of denosumab for postmenopausal women observed for up to 5 years
Postmenopausal women assigned denosumab have increases in mineral to matrix ratio at the cortical and cancellous bone at 2 to 3 years, but changes were not observed beyond 5 years, according to study findings.
Absolute appendicular lean mass best predictor of osteoporosis in menopause
Absolute appendicular lean mass appears to be a suitable marker for predicting osteoporosis based on low muscle mass for postmenopausal women, according to findings published in Menopause.
Only one-third of older women screened for osteoporosis at internal medicine clinic
Just one-third of women older than 65 years were screened for osteoporosis at an internal medicine clinic, and one-third of those diagnosed were untreated, noted a speaker at the 2021 North American Young Rheumatology Investigator Forum.
Top in endocrinology: Romosozumab vs. alendronate, health effects of shift work
Data showed that 1 year of romosozumab followed by a year of alendronate was associated with larger gains in bone mineral density at the lumbar spine than 2 years of alendronate alone in postmenopausal women with osteoporosis.
Greater lumbar spine BMD, bone strength gains with romosozumab for postmenopausal women
Postmenopausal women with osteoporosis receiving romosozumab for 12 months had larger improvements in bone mineral density and bone strength at the lumbar spine compared with those receiving alendronate alone, according to study data.